PharmAust Ltd PAA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PAA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- A$0.23
- Day Range
- A$0.22–0.24
- 52-Week Range
- A$0.07–0.54
- Bid/Ask
- A$0.22 / A$0.23
- Market Cap
- A$86.90 Mil
- Volume/Avg
- 495,045 / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 94.91
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PharmAust Ltd operates as a drug discovery and development company in Australia, Switzerland, and internationally. It develops drug discovery intellectual property for the treatment of various cancers in humans and animals. The company offers Monepantel and Albendazole, which are in Phase II clinical trials for the treatment of cancer. It also provides medicinal and synthetic chemistry services on a contract basis to the drug discovery and pharmaceutical industries.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 52
- Website
- https://www.pharmaust.com
Valuation
|
Metric
|
PAA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 11.03 |
Price/Sales | 94.91 |
Price/Cash Flow | — |
Price/Earnings
PAA
Financial Strength
|
Metric
|
PAA
|
|---|---|
Quick Ratio | 4.44 |
Current Ratio | 4.55 |
Interest Coverage | — |
Quick Ratio
PAA
Profitability
|
Metric
|
PAA
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
PAA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ygfydjdqc | Qcy | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rjvlhklk | Njpxbzz | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mcqdtqrqh | Nbbqxv | $99.2 Bil | |
MRNA
| Moderna Inc | Kfprhwtcn | Vgckt | $42.7 Bil | |
ARGX
| argenx SE ADR | Klwtqpkt | Wdztj | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Mtwlvzwgd | Lsy | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xzjlrcyk | Vzpksg | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sjjcvdc | Kfwrcs | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sgmvlthw | Zrbygm | $12.7 Bil | |
INCY
| Incyte Corp | Mkbbmwrl | Zvlmpnr | $11.9 Bil |